EC Number   |
Application |
Reference |
|---|
   2.7.1.105 | diagnostics |
the level of PFK2 is considered as a marker of glycolytic activation at tissue level |
739049 |
| 2.7.1.105 | drug development |
isozyme PFKFB4 appears to be a rational target for anti-neoplastic drug development |
730530 |
| 2.7.1.105 | medicine |
a molecule in which EDTA is covalently linked to ADP is a good starting molecule for the development of new cancer-therapeutic molecules |
665727 |
| 2.7.1.105 | medicine |
analysis of increase in cardiac glycolysis during ischemia and heart failure |
690361 |
| 2.7.1.105 | medicine |
bifunctional 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 mRNA expression is greater in metastatic prostate cancer compared with primary tumors |
721964 |
| 2.7.1.105 | medicine |
chemical enzyme PFKFB3 inhibition synergizes with erlotinib in increasing erlotinib s antiproliferative activity in NSCLC cells |
761491 |
| 2.7.1.105 | medicine |
clinical development of PFKFB3 inhibitors as chemotherapeutic agents |
694113 |
| 2.7.1.105 | medicine |
enzyme inhibition can enhance the effect of paclitaxel-based primary chemotherapy upon ovarian and breast cancers retaining wild type TP53 |
760902 |
| 2.7.1.105 | medicine |
high PFKFB3 protein and gene expression may be associated with the occurrence, development, and prognosis of esophageal squamous cell carcinoma |
761806 |
| 2.7.1.105 | medicine |
in colonic and bladder cancer cells, additive growth inhibitory effects are seen with phenformin and with an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3. The increased acidification of the culture medium and glucose uptake caused by phenformin is blocked by combined treatment with PFKFB3 inhibitors |
749587 |
